<?xml version="1.0" encoding="UTF-8"?>
<p>Importantly, sequence analysis has shown a high degree of similarity between SARS-CoV PLP and SARS-CoV2 PLP [
 <xref rid="B3-ijms-21-03492" ref-type="bibr">3</xref>,
 <xref rid="B4-ijms-21-03492" ref-type="bibr">4</xref>]. This has prompted computational screening, which has led to a number of predicted SARS-CoV2 PLP inhibitors, both clinical drugs and natural derivatives, with pre-clinical and clinical potential [
 <xref rid="B3-ijms-21-03492" ref-type="bibr">3</xref>]. Here we report a series of PLP inhibitors evaluated for other coronaviruses, that could be considered for the novel SARS-CoV2. A brief overview is given in 
 <xref rid="ijms-21-03492-t001" ref-type="table">Table 1</xref>.
</p>
